A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.

Inclusion Criteria:

• Adults aged over 18
• No recent history (within 2 years) of clinically significant medical conditionsincluding, but not limited to, malignancy (and treatment for malignancy),cardiovascular, neurological, psychiatric, renal, immunological, endocrine (includinguncontrolled diabetes or thyroid disease) or haematological abnormalities that areuncontrolled*.
• Participant's full agreement and ability to consent to participation in the study
• At least 1 migraine (not headache) episode every 2 months as classified according tothe International Classification of Headache Disorders, 3rd edition (ICHD3) formigraines published by the International Headache Society as detailed in section "Classification"
• Access to a computer or smartphone for completing online questionnaires and events.

Exclusion Criteria:

• Use of long-term medication (unless for controlled medical condition as above)
• Pregnant, trying to get pregnant or lactating women^
• Chronic past and/or current alcohol use (greater than 14 alcoholic drinks week)
• Smokers
• Allergic or hypersensitive to any of the ingredients in the active or placebo formula
• Use of preventative migraine medication
• Migraines that have reported:
• To occur on 15 or more days/month for more than 3 months, which, on at least 8days/month, has the features of migraine headache.
• A debilitating attack lasting for more than 72 hours.
• A seizure
• A medical condition will be considered uncontrolled if the participantreports ongoing treatment, a change of either medication type or dose in thepast 3 months or any change in symptoms within the past 3 months.
• Any person suspecting they may be pregnant (e.g. missed period, nausea,fatigue) will be directed to attend their GP for a pregnancy test priorto enrolment in the trial.